Bevezetés: A myositisek a proximalis végtagizmok gyengeségével jellemezhető autoimmun betegségek. Célkitűzés: A szerzők célul tűzték ki a dermatomyositis-specifikus antitestek (anti-Mi-2, anti-transcriptional intermediary factor 1 gamma, anti-nuclear matrix protein 2, anti-small ubiquitin-like modifier activating enzyme, anti-melanoma differentiation-associated gene 5) gyakoriságának felmérését hazai myositises populációban. Klinikai jellemzőiket és laboratóriumi paramétereiket összehasonlították a myositisspecifikus antitesttel nem rendelkező betegek adataival. Módszer: Az autoantitest-meghatározás immunoblottal, illetve immunprecipitációval történt. Eredmények: 330 myositises beteg közül 48 dermatomyositis-specifikus autoantitest-pozitív beteg adatait dolgozták fel és elemezték retrospektív módon. A vizsgált antitestek összességében ritkábban fordultak elő a vizsgált magyar populációban, mint a nemzetközi tanulmányokban. Megfigyelték, hogy a dermatomyositis-specifikus antitesttel rendelkező betegeknél jellemző volt az akut, súlyosabb izomgyengeséggel járó kezdet, amely a legtöbb esetben jellegzetes bőrtünetekkel társult. Következtetések: A myositisspecifikus antitestek meghatározása segítséget ad a beteg tüneteinek differenciálásában, felvilágosítást nyújt a várható lefolyásról és segítheti a megfelelő terápia megválasztását. Orv. Hetil., 2015, 156(36), 1451–1459.
Selva-O’Callaghan, A., Trallero-Araguás, E., Martínez, M. A., et al.: Inflammatory myopathy: diagnosis and clinical course, specific clinical scenarios and new complementary tools. Expert Rev. Clin. Immunol., 2015, 11(6), 737–747.
Mahler, M., Miller, F. W., Fritzler, M. J.: Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun. Rev., 2014, 13(4–5), 367–371.
Takeda, Y., Wang, G. S., Wang, R. J., et al.: Enzyme-linked immunosorbent assay using isolated (U) small nuclear ribonucleoprotein polypeptides as antigens to investigate the clinical significance of autoantibodies to these polypeptides. Clin. Immunol. Immunopathol., 1989, 50(2), 213–230.
La Corte, R., Lo Monaco, A., Locaputo, A., et al.: In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity, 2006, 39(3), 249–253.
Váncsa, A, Csípő, I, Németh, J, et al.: Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol. Int., 2009, 29(9), 989–994.
Wang, J., Satoh, M., Kabir, F., et al.: Increased prevalence of autoantibodies to Ku antigen in African American versus white patients with systemic lupus erythematosus. Arthritis Rheum., 2001, 44(10), 2367–2370.
Cooley, H. M., Melny, B. J., Gleeson, R., et al.: Clinical and serological associations of anti-Ku antibody. J. Rheumatol., 1999, 26(3), 563–567.
Franceschini, F., Cavazzana, I., Generali, D., et al.: Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. J. Rheumatol., 2002, 29(7), 1393–1397.
Mohanna, M., Distler, O., Sprott, H., et al.: Skin lesions in anti-Pm-Scl-70 positive systemic sclerosis-dermatomyositis overlap syndrome improve during local PUVA phototherapy. Eur. J. Dermatol., 2013, 23(5), 730–731.
Targoff, I. N.: Update on myositis-specific and myositis-associated autoantibodies. Curr. Opin. Rheumatol., 2000, 12(6), 475–481.
Brouwer, R., Hengstman, G. J., Vree Egberts, W., et al.: Autoantibody profiles in the sera of European patients with myositis. Ann. Rheum. Dis., 2001, 60(2), 116–123.
Lega, J. C., Fabien, N., Reynaud, Q., et al.: The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun. Rev., 2014, 13(9), 883–891.
Liang, C., Needham, M.: Necrotizing autoimmune myopathy. Curr. Opin. Rheumatol., 2011, 23(6), 612–619.
Bodoki, L., Vincze, M., Hortobágyi, T., et al.: Necrotizing autoimmune myopathy. [Nekrotizáló autoimmun myopathia.] Orv. Hetil., 2012, 153(38), 1502–1507. [Hungarian]
Allenbach, Y., Drouot, L., Rigolet, A., et al.: Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore), 2014, 93(3), 150–157.
Christopher-Stine, L., Casciola-Rosen, L., Hong, G., et al.: A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum., 2010, 62(9), 2757–2766.
Pluk, H., van Hoeve, B. J., van Dooren, S. H., et al.: Autoantibodies to cytosolic 5’-nucleotidase 1A in inclusion body myositis. Ann. Neurol., 2013, 73(3), 397–407.
Targoff, I. N., Reichlin, M.: The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum., 1985, 28(7), 796–803.
ORGENTEC Diagnostika GmbH Myositis plus Instruction for use. http://www.orgentec.com/products/pdfs/IFU_ELISA_Blot_EN/ORG%20760_IFU_EN_QM113220_2012-11-27_1.1.pdf
Gunawardena, H., Wedderburn, L. R., North, J., et al.: Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford), 2008, 47(3), 324–328.
Rider, L. G., Koziol, D., Giannini, E. H., et al.: Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res. (Hoboken), 2010, 62(4), 465–472.
Kendall, F. P., McCreary, E. K., Provance, P. G.: Muscles: testing and function. 4th ed. Williams and Wilkins, Baltimore, 1993.
Somogyi, B., Trón, L.: Elements of biometrics. [Biometriai alapfogalmak.] Debreceni Egyetemi Kiadó, Debrecen, 2010. [Hungarian]
Betteridge, Z. E., Gunawardena, H., McHugh, N. J.: Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res. Ther., 2011, 13(2), 209.
Tansley, S. L., Betteridge, Z. E., McHugh, N. J.: The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr. Opin. Rheumatol., 2013, 25(6), 772–777.
Cruellas, M. G., Viana Vdos, S., Levy-Neto, M., et al.: Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics (São Paulo), 2013, 68(7), 909–914.
Petri, M. H., Satoh, M., Martin-Marquez, B. T., et al.: Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res. Ther., 2013, 15(2), R48.
Selva-O’Callaghan, A., Labrador-Horrillo, M., Solans-Laque, R., et al.: Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum., 2006, 55(5), 791–798.
Targoff, I. N., Mamyrova, G., Trieu, E. P., et al.: A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arhtritis Rheum., 2006, 54(11), 3682–3689.
Ichimura, Y., Matsushita, T., Hamaguchi, Y., et al.: Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann. Rheum. Dis., 2012, 71(5), 710–713.
Ceribelli, A., Fredi, M., Taraborelli, M., et al.: Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res. Ther., 2012, 14(2), R97.
Betteridge, Z. E., Gunawardena, H., Chinoy, H., et al.: Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann. Rheum. Dis., 2009, 68(10), 1621–1625.
Tarricone, E., Ghirardello, A., Rampudda, M., et al.: Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J. Immunol. Methods, 2012, 384(1–2), 128–134.
Labrador-Horrillo, M., Martinez, M. A., Selva-O’Callaghan, A., et al.: Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J. Immunol. Res., 2014, 2014, 290797.
Hamaguchi, Y., Kuwana, M., Hoshino, K., et al.: Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch. Dermatol., 2011, 147(4), 391–398.
Fiorentino, D., Chung, L., Zwerner, J., et al.: The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J. Am. Acad. Dermatol., 2011, 65(1), 25–34.
Dankó, K.: Inflammatory muscular diseases. In: Czirják, L. (ed.): Clinical immunology. [Gyulladásos izombetegségek. In: Czirják, L. (szerk.): Klinikai immunológia.] Medicina Könyvkiadó, Budapest, 2006. [Hungarian]
Hengstman, G. J., Vree Egberts, W. T., Seelig, H. P., et al.: Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann. Rheum. Dis., 2006, 65(2), 242–245.
Peixoto, D., Costa, J., Ferretti, M., et al.: New autoantibodies and their clinical associations in juvenile myositis – a systematic review. Acta Reumatol. Port., 2013, 38(4), 234–241.
Valenzuela, A., Chung, L., Casciola-Rosen, L., et al.: Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol., 2014, 150(7), 724–729.
Fujimoto, M.: Myositis-specific autoantibodies. Brain Nerve, 2013, 65(4), 449–460. [Japanese]
Bodoki, L., Nagy-Vincze, M., Griger, Z., et al.: Four dermatomyositis-specific autoantibodies–anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5–in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun. Rev., 2014, 13(12), 1211–1219.